Trial · NCT07095933
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
NCT07095933, Early phase 1, Recruiting, Xuanwu Hospital, Beijing
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy. Trials, record NCT07095933. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07095933
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
- NCT number
- NCT07095933
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 5 participants, estimated
- Lead sponsor
- Xuanwu Hospital, Beijing
- Conditions
- Epilepsy, Drug Resistant
- Interventions
- Everolimus
- First posted
- 2025-07-31
- Last updated
- 2026-04-07
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change From Baseline in Seizure Frequency Per 28 Days | assessed per 28 days during the treatment until the end of 12-week treatment. | Percent change in 28-day frequency of seizures during the 12 week treatment and follow-up period relative to baseline |
| Secondary | 50% Seizure Responder Rate | Baseline observation period, and 12-week treatment period (ending at 12 weeks). | The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency. |
| Secondary | Seizure Severity | Baseline observation period, and 12-week treatment period (ending at 12 weeks). | The percent change from baseline in seizure severity evaluated by Liverpool seizure severity scale (LSSS) . |
| Secondary | Life quality evaluation | Baseline observation period, and 12-week treatment period (ending at 12 weeks). | Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31) score. |
| Secondary | Adverse Events | through study completion, 12 weeks. | Rate of adverse events which were judged to be study-related throughout the study. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07095933
GET https://conductscience.org/api/trials/v1/NCT07095933/registered